Pembrolizumab significantly extended DFS among patients with completely resected stage IB to stage III non-small cell lung cancer, irrespective of PD-L1 expression, according to a study presented during an ESMO Virtual Plenary session.
Results of the randomized phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS, further showed the anti-PD-1 antibody had a safety profile consistent with that observed in prior studies.
Pembrolizumab (Keytruda, Merck) has become a standard of care for advanced NSCLC. The KEYNOTE-091 trial investigated use of the agent vs. placebo in